Tesi Raymond Joseph's Form 4 filing
Inmune Bio, Inc. (INMB) · filed May 31, 2022
- Accession no.
- 0001213900-22-030210
- Filed
- May 31, 2022
- Trade date
- May 26, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $40.4K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tesi Raymond JosephCIK 0001767280 | Director, Officer (President and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 26, 2022 | Common Stock | PPurchaseAcquired | +6,300 | $6.41F1 | +$40,383 | 1,520,698 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the average purchase price at a range of between $6.37 and $6.43 per share.
Referenced by the price of 1 transaction in Table I.